Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

NCT07085728 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

74

Enrollment

NETWORK

Sponsor class

Conditions

Myeloma Multiple

Interventions

DRUG: Cyclophosphamide
DRUG: Bortezomib (VELCADE)
DRUG: Dexamethasone
DRUG: Daratumumab-hyaluronidase

Sponsor

Eastern Cooperative Oncology Group

Collaborators

[object Object]